Parallel Discharging Parallel discharging can be used, but only under strict conditions
However Lillys demonstration that a GIP/GLP-1 receptor co-agonist (tirzepatide) has superior efficacy compared to selective GLP-1 receptor agonists, has renewed interest in the first incretin. Lilly rolled out their SURPASS trials to position their agent amongst existing diabetes medications and GLP-1 agonists
Xin P, Pan Y, Zhu W, et al
In one study from Israel, researchers compared this standard schedule with a slower increase that took 16 weeks to reach a 1 mg dose
That means it could be more effective when taken orally no needles required
The improvement in the TyG index and to a lesser extend the HOMA-IR is to be expected as the FPG levels improved significantly following linagliptin intervention in the high GLP-1 group of both the prediabetes and T2D populations despite the non-significant drop in the fasting insulin levels